Artelo Biosciences, Inc. ARTL
Set alert
2.17 USD -0.06 -2.69%
At close
2.24 +0.07 +3.23%
Pre-market · Nov 3, 4:00 AM ET
2.12 Day range 2.27
2.05 52-week range 179.19
- YTD
- -93.41%
- 1 year
- -97.32%
- Open
- 2.22
- Prev close
- 2.23
- Mkt cap
- 1.19M
- Vol
- 45.03K
- Avg vol
- 484.24K
- EPS
- -136.26
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.12
- High
- 2.27
- Forward P/E
- -1.10
- Beta
- 1.35
- Short ratio
- 1.65
- Inst. own
- 0.72%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 13, 2024
- 50-d avg
- 1.13
- 200-d avg
- 1.28
- 1y target
- 5.00
News
-
4 days ago benzinga.com
Artelo Biosciences To Present Data For Its ART27.13 To Treat Chemotherapy-Induced Neuropathic Pain At IASP 2026 World Congress On Pain
Artelo Biosciences, Inc. (Nasdaq: ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with
4 days ago globenewswire.com
Artelo Biosciences to Present ART27.13 Data Demonstrating Potential to Treat Chemotherapy-Induced Neuropathic Pain at the IASP 2026 World Congress on Pain
Nonclinical studies demonstrated reductions in two key measures of neuropathic pain Ongoing Phase 2 CAReS trial includes pain endpoints to evaluate ART27.13's potential to address multiple…
-
1 week ago benzinga.com
Artelo Bioscience To Present Data On ART26.12 Program At IASP 2026 World Congress On Pain, October 26–30; Growing Body Of Data Supports ART26.12’s Potential As A Novel, Non-Opioid Treatment For Pain Ahead Of Planned Multiple Ascending Dose Study
Artelo Biosciences, Inc. (NASDAQ:ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with